Cargando…
Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People’s Republic of China
The burden of methicillin-resistant Staphylococcus aureus (MRSA) nosocomial pneumonia in the People’s Republic of China is high, with methicillin-resistance rates greater than 80% reported for patients with S. aureus pneumonia treated in intensive care units. Historically, vancomycin was the treatme...
Autores principales: | Lesher, Beth, Gao, Xin, Chen, Yixi, Liu, Zhengyin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818060/ https://www.ncbi.nlm.nih.gov/pubmed/27069370 http://dx.doi.org/10.2147/CEOR.S91985 |
Ejemplares similares
-
Linezolid for the treatment of hospital-acquired pneumonia in a Chinese tertiary hospital
por: Lesher, Beth A, et al.
Publicado: (2015) -
Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
por: Patel, Dipen A, et al.
Publicado: (2014) -
Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy
por: Pletz, Mathias W, et al.
Publicado: (2010) -
An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany
por: Patel, Dipen A, et al.
Publicado: (2014) -
Pneumonia Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus: Vancomycin or Linezolid?
por: Tian, Ye, et al.
Publicado: (2018)